Solid Biosciences LLC - Asset Resilience Ratio
Solid Biosciences LLC (SLDB) has an Asset Resilience Ratio of 19.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Solid Biosciences LLC's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Solid Biosciences LLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Solid Biosciences LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SLDB company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $83.58 Million | 19.76% |
| Total Liquid Assets | $83.58 Million | 19.76% |
Asset Resilience Insights
- Good Liquidity Position: Solid Biosciences LLC maintains a healthy 19.76% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Solid Biosciences LLC Industry Peers by Asset Resilience Ratio
Compare Solid Biosciences LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Solid Biosciences LLC (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Solid Biosciences LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.02% | $127.95 Million | $232.54 Million | +18.62pp |
| 2024-12-31 | 36.41% | $68.69 Million | $188.66 Million | +6.32pp |
| 2023-12-31 | 30.09% | $49.62 Million | $164.94 Million | +7.67pp |
| 2022-12-31 | 22.42% | $58.34 Million | $260.25 Million | -15.73pp |
| 2021-12-31 | 38.15% | $88.64 Million | $232.38 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $171.17 Million | -- |
| 2019-12-31 | 7.23% | $7.48 Million | $103.47 Million | -18.63pp |
| 2018-12-31 | 25.86% | $36.10 Million | $139.60 Million | +3.53pp |
| 2017-12-31 | 22.33% | $17.01 Million | $76.19 Million | -51.45pp |
| 2016-12-31 | 73.78% | $29.98 Million | $40.64 Million | +25.67pp |
| 2015-12-31 | 48.10% | $26.79 Million | $55.70 Million | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more